CD19 and autoimmune thrombocytopenic purpura: Studies have demonstrated that the increased number of CD19+CD24highCD38high B cells (transitional B cells) and pre-germinal center B cells reflects an activated autoimmune response and may predict the future treatment response in untreated ITP patients [51].